Citations

Mayo Clinic

Showing 10 of 108523 citations.

Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non‐sensitized renal transplant patients treated with rapid steroid withdrawal
Saull, Harrison E., Enderby, Cher Y. , Gonwa, Thomas A., Wadei, Hani M. , Wadei, Hani M

Clinical Transplantation | February 25, 2015 | Volume: 29 | Issue: 7 | Pages: 573-580

10.1111/ctr.12532 | PMID 25711849 Get It

AbstractAlemtuzumab and rabbit antithymocyte globulin (rATG) are commonly used for induction therapy in renal transplantation. This retrospective, single‐center, cohort study evaluated cumulative incidence of one‐yr biopsy‐proven acute rejection (BPAR) among 200 consecutive primary non‐sensitized kidney transplant recipients who received either alemtuzumab (n = 100) or rATG (n = 100) induction followed by rapid steroid taper, tacrolimus, and mycophenolate mofetil. Protocol biopsies, plasma and urine BK virus PCR, serum creatinine and iothalamate glomerular filtration rate (iGFR), were obtained at 1, 4, and 12 months from transplantation. The one‐yr BPAR rates were similar between the alemtuzumab and rATG groups; however, rejection Banff IA and higher was more common in the alemtuzumab arm (18% vs. 5%, p = 0.047). After adjusting for confounding variables, alemtuzumab was still associated with Banff IA and higher rejection (adjusted OR: 3.7, CI: 1.2–10.5, p = 0.02). Despite similar rates of BK viremia, more patients in the alemtuzumab arm developed BK nephropathy (16% vs. 3%, p = 0.046). One‐year iGFR (53.4 ± 20.2 vs. 71.9 ± 27.2 mL/min/1.73 m2, p = 0.002) and three‐yr graft survival (89.5% vs. 95%, p = 0.05) were lower in the alemtuzumab group. In low immunological risk kidney transplant recipients on steroid‐free immunosuppression, alemtuzumab was associated with more severe rejection and BK nephropathy compared to rATG.
SPE HSE Conference Identifies Challenges and Opportunities for the 21st Century
Visser, Koos, Roger, J, Ognedal, Magne, Strecker, Ian, Corrie, Carlos C., Thoem, T., Hassanali, Khalid M., Molenaar, Donald M.

Journal of Petroleum Technology | February 24, 2015 | Volume: 51 | Issue: 04 | Pages: 22-24

10.2118/0499-0022-jpt Get It

Conference review - No abstract available.
Trends in the Proportion of Patients With Lung Cancer Meeting Screening Criteria
Wang, Yi , Midthun, David E. , Wampfler, Jason A. , Deng, Bo , Stoddard, Shawn M., Zhang, Shuo , Zhang, Shuo , Yang, Ping

JAMA | February 24, 2015 | Volume: 313 | Issue: 8 | Pages: 853

10.1001/jama.2015.413 | PMID 25710663 Get It

Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma
Zaanan, Aziz , Park, Jae Myung , Tougeron, David , Huang, Shengbing, Wu, Tsung‐Teh, Foster, Nathan R. , Sinicrope, Frank A. , Tougeron, David

International Journal of Cancer | February 24, 2015 | Volume: 137 | Issue: 6 | Pages: 1498-1502

10.1002/ijc.29496 | PMID 25708267 Get It

Flexible endosopic management of Zenker's diverticulum: characteristics and outcomes of 52 cases at a tertiary referral center
Halland, Magnus , Grooteman, Karina V. , Baron, Todd H.

Diseases of the Esophagus | February 24, 2015 | Volume: 29 | Issue: 3 | Pages: 273-277

10.1111/dote.12323 | PMID 25708598 Get It

Adult Primary Central Nervous System Vasculitis Treatment and Course: Analysis of One Hundred Sixty‐Three Patients
Salvarani, Carlo , Brown, Robert D. , Christianson, Teresa J., Miller, Dylan V. , Hunder, Gene G. , Christianson, Teresa J H, Salvarani, Carlo , Huston, John , Giannini, Caterina

Arthritis & Rheumatology | February 23, 2015 | Volume: 67 | Issue: 6 | Pages: 1637-1645

10.1002/art.39068 | PMID 25708615 Get It

Objective To describe the treatment and outcomes of patients with primary central nervous system (CNS) vasculitis. Methods We retrospectively studied a cohort of 163 consecutive patients with primary CNS vasculitis who were seen at the Mayo Clinic over a 29‐year period. We analyzed treatments, treatment responses, and factors predictive of outcomes. Results A favorable response was observed in 85% of patients treated with prednisone alone and in 80% of patients treated with prednisone and cyclophosphamide. Relapses were observed in 27% of patients, and 25% of patients had discontinued therapy by the time of the last followup visit. Treatment with prednisone alone was associated with more frequent relapses (odds ratio [OR] 2.90), while large vessel involvement (OR 6.14) and cerebral infarcts at the time of diagnosis (OR 3.32) were associated with a poor response to treatment. Prominent gadolinium‐enhanced cerebral lesions or meninges were linked with continued treatment at the last followup encounter (OR 2.28). Higher disability scores at the last followup visit were associated with increasing age at the time of diagnosis (OR 1.44) and cerebral infarctions (OR 3.74), while lower disability scores were associated with gadolinium‐enhanced cerebral lesions or meninges (OR 0.35) and cerebral amyloid angiopathy (OR 0.24). Increased mortality was associated with increasing age at diagnosis (hazard ratio [HR] 1.39), diagnosis by angiography (HR 3.28), cerebral infarction (HR 4.44), and large vessel involvement (HR 4.98), while reduced mortality was associated with gadolinium‐enhanced cerebral lesions or meninges (HR 0.20). Conclusion The majority of patients with primary CNS vasculitis responded to treatment. Recognition of findings at diagnosis that predict the course or outcome may aid in decision‐making regarding therapy.
Exome sequencing establishes diagnosis of Alström syndrome in an infant presenting with non‐syndromic dilated cardiomyopathy
Long, Pamela A., Evans, Jared M., Olson, Timothy M. , Olson, Timothy M

American Journal of Medical Genetics Part A | February 23, 2015 | Volume: 167 | Issue: 4 | Pages: 886-890

10.1002/ajmg.a.36994 | PMID 25706677 Get It

Idiopathic dilated cardiomyopathy is a heritable, genetically heterogeneous disorder characterized by progressive heart failure. Dilated cardiomyopathy typically exhibits autosomal dominant inheritance, yet frequently remains clinically silent until adulthood. We sought to discover the molecular basis of idiopathic, non‐syndromic dilated cardiomyopathy in a one‐month‐old male presenting with severe heart failure. Previous comprehensive testing of blood, urine, and skin biopsy specimen was negative for metabolic, mitochondrial, storage, and infectious etiologies. Ophthalmologic examination was normal. Chromosomal microarray and commercial dilated cardiomyopathy gene panel testing failed to identify a causative mutation. Parental screening echocardiograms revealed no evidence of clinically silent dilated cardiomyopathy. Whole exome sequencing was carried out on the family trio on a research basis, filtering for rare, deleterious, recessive and de novo genetic variants. Pathogenic compound heterozygous truncating mutations were identified in ALMS1, diagnostic of Alström syndrome and prompting disclosure of genetic findings. Alström syndrome is a known cause for dilated cardiomyopathy in children yet delayed and mis‐diagnosis are common owing to its rarity and age‐dependent emergence of multisystem clinical manifestations. At six months of age the patient ultimately developed bilateral nystagmus and hyperopia, features characteristic of the syndrome. Early diagnosis is guiding clinical monitoring of other organ systems and allowing for presymptomatic intervention. Furthermore, recognition of recessive inheritance as the mechanism for sporadic disease has informed family planning. This case highlights a limitation of standard gene testing panels for pediatric dilated cardiomyopathy and exemplifies the potential for whole exome sequencing to solve a diagnostic dilemma and enable personalized care. © 2015 Wiley Periodicals, Inc.
Disclosing genetic risk for coronary heart disease: effects on perceived personal control and genetic counseling satisfaction
Robinson, Christopher L , Jouni, H, Kruisselbrink, Teresa , Austin, Erin , Christensen, Kurt D. , Green, R.C., Kullo, Iftikhar J.

Clinical Genetics | February 23, 2015 | Volume: 89 | Issue: 2 | Pages: 251-257

10.1111/cge.12577 | PMID 25708169 Get It

We investigated whether disclosure of coronary heart disease (CHD) genetic risk influences perceived personal control (PPC) and genetic counseling satisfaction (GCS). Participants (n = 207, age: 45–65 years) were randomized to receive estimated 10‐year risk of CHD based on a conventional risk score (CRS) with or without a genetic risk score (GRS). Risk estimates were disclosed by a genetic counselor who also reviewed how GRS altered risk in those randomized to CRS+GRS. Each participant subsequently met with a physician and then completed surveys to assess PPC and GCS. Participants who received CRS+GRS had higher PPC than those who received CRS alone although the absolute difference was small (25.2 ± 2.7 vs 24.1 ± 3.8, p = 0.04). A greater proportion of CRS+GRS participants had higher GCS scores (17.3 ± 5.3 vs 15.9 ± 6.3, p = 0.06). In the CRS+GRS group, PPC and GCS scores were not correlated with GRS. Within both groups, PPC and GCS scores were similar in patients with or without family history (p = NS). In conclusion, patients who received their genetic risk of CHD had higher PPC and tended to have higher GCS. Our findings suggest that disclosure of genetic risk of CHD together with conventional risk estimates is appreciated by patients. Whether this results in improved outcomes needs additional investigation.
The role of families in decisions regarding cancer treatments
Hobbs, Gabriela , Landrum, Mary Beth , Arora, Neeraj K. , Ganz, Patricia A. , Ryn, Michelle van , Weeks, Jane C., Mack, Jennifer W. , Keating, Nancy L. , Hobbs, Gabriela S , van Ryn, Michelle

Cancer | February 23, 2015 | Volume: 121 | Issue: 7 | Pages: 1079-1087

10.1002/cncr.29064 | PMID 25708952 Get It

BACKGROUNDShared decision‐making is an important component of patient‐centered care and is associated with improved outcomes. To the authors' knowledge, little is known concerning the extent and predictors of the involvement of a patient's family in decisions regarding cancer treatments.METHODSThe Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium is a large, multiregional, prospective cohort study of the cancer care and outcomes of patients with lung and colorectal cancer. Participants reported the roles of their families in decision‐making regarding treatment. Multinomial logistic regression was used to assess patient factors associated with family roles in decisions.RESULTSAmong 5284 patients, 80 (1.5%) reported family‐controlled decisions, with the highest adjusted rates (12.8%) noted among non‐English‐speaking Asians. Among the 5204 remaining patients, 49.4% reported equally sharing decisions with family, 22.1% reported some family input, and 28.5% reported little family input. In adjusted analyses, patients who were married, female, older, and insured more often reported equally shared decisions with family (all P <.001). Adjusted family involvement varied by race/ethnicity and language, with Chinese‐speaking Asian (59.8%) and Spanish‐speaking Hispanic (54.8%) patients equally sharing decisions with family more often than white individuals (47.6%). Veterans Affairs patients were least likely to report sharing decisions with family, even after adjustment for marital status and social support (P <.001).CONCLUSIONSThe majority of patients with newly diagnosed lung or colorectal cancer involve family members in treatment decisions. Non‐English‐speaking Asians and Hispanics rely significantly on family. Further studies are needed to determine the impact of family involvement in treatment decisions on outcomes; until then, physicians should consider eliciting patients' preferences for family involvement. Cancer 2015;121:1079–1087. © 2015 American Cancer Society.
Trochanteric Micropuncture: Treatment for Gluteus Medius Tendinopathy
Redmond, John M., Cregar, William M., Gupta, Asheesh, Hammarstedt, Jon E. , Martin, Timothy J. , Domb, Benjamin G.

Arthroscopy Techniques | February 23, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.1016/j.eats.2014.11.009 | PMID 25973381 Get It

Abstract Lateral hip pain along with tenderness of the greater trochanter has been associated with greater trochanteric pain syndrome. Radiographically, this has been associated with gluteus medius pathology on magnetic resonance imaging. This has led some surgeons to conclude that abductor pathology is a primary cause of lateral hip pain. Failure of conservative treatment in the setting of gluteus medius pathology may lead to surgical intervention. In some patients a focal tear of the gluteus medius cannot be visualized and likely represents more diffuse tendinopathy. In these patients we propose micropuncture of the greater trochanter. Similar procedures have shown effectiveness in the elbow and shoulder by eliciting a healing response. Our experience suggests that trochanteric micropuncture at the insertion of the gluteus medius tendon can be effectively performed endoscopically for gluteus medius tendinopathy. Technique Video video See video under supplementary data.